

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/808,031	03/03/1997		SUMIKO INOUYE	377.5888P	5819
35811	7590	11/03/2004		EXAMINER	
IP DEPARTMENT OF PIPER RUDNICK LLP				HUTSON, RICHARD G	
ONE LIBER	TY PLAC	CE, SUITE 4900			
1650 MARKET ST				ART UNIT	PAPER NUMBER
PHILADELPHIA, PA 19103				1652	

DATE MAILED: 11/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>						
	Application No.	Applicant(s)				
	08/808,031	INOUYE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Richard G. Hutson	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	 1. 1.136(a). In no event, however, may a reply be ti eply within the statutory minimum of thirty (30) da bd will apply and will expire SIX (6) MONTHS fron ute, cause the application to become ABANDON! 	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status	•					
1) Responsive to communication(s) filed on <u>08</u>	July 2004.					
,—	nis action is non-final.					
3) Since this application is in condition for allow	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1,5,7,12,17 and 18 is/are pending in 4a) Of the above claim(s) is/are withdrest is/are withdrest is/are allowed. 5) Claim(s) 7 is/are allowed. 6) Claim(s) 1,5,12,17 and 18 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and are subject to restriction and subject is are subject to by the Examination of the drawing(s) filed on is/are: a) and an applicant may not request that any objection to the subjection to the subjection is objection is objection is objection to the subjection is objection is obj	rawn from consideration. d/or election requirement. iner. ccepted or b) □ objected to by the he drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s)/Mail Date					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date		Patent Application (PTO-152)				

Art Unit: 1652

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/8/2004 has been entered.

Applicants amendment of claims 1, 5, 7, 12 and 17, cancellation of claims 2, 4, 6, 8, 10 and 15, and the addition of new claim 18, in Paper of 7/8/2004, is acknowledged. Claims 1, 5, 7, 12, 17 and 18 are still at issue and are present for examination.

Applicants' arguments filed on 7/8/2004 have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied.

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 5, 12, 17 and 18 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as

Art Unit: 1652

to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1, 5, 12, 17 and 18 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification because applicants amendment of claim 1 which recites "...a fifth sequence of amino acid residues as follows: Gly-Xaa8-Pro, wherein Xaa8 is selected from the group consisting of alanine, phenylalanine or serine" is not supported by the original specification and thus considered new matter. Applicants Remarks/Argument regarding support for this amendment being found in Fig. 14 of the Applicants' specification, more particularly in the 4th boxed sequence in Fig 14, row three, are acknowledged however not found persuasive that applicants had support for such a claimed genus at the time of filing of the instant application. While it is recognized that such a sequence does exist, along with a number of different additional sequences, this does not support the current claim to that genus of bacterial reverse transcriptases having the specified limitation.

Claim 18 is further rejected under 35 U.S.C. 112, first paragraph, written description, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The instant claim is drawn to a bacterial reverse transcriptase of claim 1, wherein said bacterial reverse transcriptase is derived from *Myxococcus xanthus* or *Escherchia coli*.

Art Unit: 1652

The Court of Appeals for the Federal Circuit has recently held that a "written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as be structure, formula [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials."

University of California v. Eli Lilly and Co., 1997 U.S. App. LEXIS 18221, at *23, quoting Fiers v. Revel, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) (bracketed material in original).

To fully describe a genus of genetic material, which is a chemical compound, applicants must (1) fully describe at least one species of the claimed genus sufficient to represent said genus whereby a skilled artisan, in view of the prior art, could predict the structure of other species encompassed by the claimed genus and (2) identify the common characteristics of the claimed molecules, e.g., structure, physical and/or chemical characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or a combination of these.

In the instant specification, a bacterial reverse transcriptase is fully described in the form of SEQ ID NO:2. This description also adequately describes a genus, within the certain sequence identity limitations of the instant claims, of bacterial reverse transcriptases. Those sequences that are "derived from *Myxococcus xanthus* or *Escherchia coli*." are a subset of this genus. The specification does not adequately describe this subset according to its structure so that one of skill in the art would be able to predict naturally occurring sequences, particularly in view of the larger genus that includes both naturally and "manufactured" sequences. Therefore, the instant claims are not adequately described.

Art Unit: 1652

Applicant is referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at www.uspto.gov.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The rejection of claims 1, 2, 5, 6, 8, 10, 15 and 16 under 35 U.S.C. 102(b) as being anticipated by Lim and Mass (Cell 56:891-904, 1989) is hereby withdrawn based on applicant amendment of the claims.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The rejection of claims 1, 2, 4-8 and 15-17 under 35 U.S.C. 103(a) as being unpatentable over either of Inouye et al. (US Pat. 5,320,958 or US Pat. 5,434,070), in view of the combination of Rice et al. (July 1993), Xiong et al. (1990) and Hsu et al.

Art Unit: 1652

(Apr. 1992) is hereby withdrawn in light of applicants filing of a declaration under 1.130 and applicants supporting traversal in the paper of 7/8/2004.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G Hutson whose telephone number is (703) 308-0066. The examiner can normally be reached on 7:30 am to 4:00 pm, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (703) 308-3804. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Richard G Hutson, Ph.D. Primary Examiner Art Unit 1652

rgh 10/28/2004